Study designs needing the two compounds at independent concentrations should use the separate CJC-1295 and Ipamorelin vials instead
Semaglutide offers more safety data and an oral option
OTHER INGREDIENTS Thiamine (Vitamin B1), Riboflavin (Vitamin B2), Niacinamide (Vitamin B3), d-Panthenol (pro-Vitamin B5), Pyridoxine (Vitamin B6), Folic Acid (Vitamin B9), Ascorbic Acid (Vitamin C), Vitamin A, Vitamin D, Levocarnitine, Dextrose
Signal Amplification: Activated receptors trigger G-protein coupling, adenylyl cyclase activation, and dramatic increases in intracellular cAMP (often 10-100 fold elevation)
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved